Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)

v3.24.1.1.u2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Treasury stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2022   2,063,074,000        
Beginning balance at Dec. 31, 2022 $ 24,881 $ 0 $ 0 $ 275,572 $ (250,219) $ (472)
Beginning balance (in shares) at Dec. 31, 2022     0      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares (in shares)   1,895,000        
Exercise of stock options, net of vesting of restricted shares 58     58    
Release of restricted stock (in shares)   16,977,000        
Issuance of common stock in lieu of cash bonus & consulting fees (in shares)   7,454,000        
Issuance of common stock in lieu of cash bonus & consulting fees 347     347    
Common stock issued upon conversion of 2022 Promissory Note 0          
Stock-based compensation expense 1,336     1,336    
Cumulative translation adjustment 23         23
Treasury stock repurchase (in shares)     (9,230,000)      
Treasury stock repurchase (475)   $ (475)      
Net loss (4,269)       (4,269)  
Ending balance (in shares) at Mar. 31, 2023   2,089,400,000        
Ending balance at Mar. 31, 2023 21,901 $ 0 $ (475) 277,313 (254,488) (449)
Ending balance (in shares) at Mar. 31, 2023     (9,230,000)      
Beginning balance (in shares) at Dec. 31, 2022   2,063,074,000        
Beginning balance at Dec. 31, 2022 $ 24,881 $ 0 $ 0 275,572 (250,219) (472)
Beginning balance (in shares) at Dec. 31, 2022     0      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Treasury stock repurchase (in shares) (10,130)          
Treasury stock repurchase $ (502)          
Ending balance (in shares) at Dec. 31, 2023 3,851,448 3,861,578,000        
Ending balance at Dec. 31, 2023 $ (11,457) $ 0 $ (502) 292,467 (303,004) (418)
Ending balance (in shares) at Dec. 31, 2023 (10,130)   (10,130,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Release of restricted stock (in shares)   16,000,000        
Issuance of common stock in lieu of cash bonus & consulting fees (in shares)   11,453,000        
Issuance of common stock in lieu of cash bonus & consulting fees $ 35     35    
Common stock issued upon conversion of 2022 Promissory Note (in shares)   336,550,000        
Common stock issued upon conversion of 2022 Promissory Note 4,505     4,505    
Sale of common stock & exercise of prefunded warrants, net of issuance costs (in shares)   3,915,009,000        
Sale of common stock & exercise of prefunded warrants, net of issuance costs 23,204 $ 1   23,203    
Fractional share issuances as a result of reverse stock split (in shares)   141,631,000        
Stock-based compensation expense 630     630    
Cumulative translation adjustment 0          
Net loss $ (2,292)       (2,292)  
Ending balance (in shares) at Mar. 31, 2024 8,272,091 8,282,221,000        
Ending balance at Mar. 31, 2024 $ 14,625 $ 1 $ (502) $ 320,840 $ (305,296) $ (418)
Ending balance (in shares) at Mar. 31, 2024 (10,130)   (10,130,000)